Table IV.
Forward step multivariate modifications of sex in association with overall survival.
| Model | Modifications | Sex HR | (95% CI) | P-value |
|---|---|---|---|---|
| A | Crude (sex only) | 0.564 | (0.456–0.697) | 0.0001 |
| B | Model A+histology 1 | 0.600 | (0.455–0.790) | 0.0001 |
| C | Model B+age | 0.600 | (0.455–0.790) | 0.0001 |
| D | Model C+Breslow's thickness | 0.580 | (0.431–0.795) | 0.001 |
| E | Model D+Clark's level | 0.579 | (0.422–0.796) | 0.001 |
| F | Model E+mitotic rate | 0.588 | (0.418–0.827) | 0.002 |
| G | Model F+ulceration | 0.593 | (0.418–0.839) | 0.003 |
| H | Model G+node 1 | 0.580 | (0.389–0.863) | 0.007 |
| I | Model H+metastasis 1 | 0.587 | (0.395–0.874) | 0.009 |
| J | Model I+recurrence | 0.600 | (0.399–0.901) | 0.014 |
| K | Model J+site of lesion | 0.600 | (0.399–0.901) | 0.014 |
| L | Model K+regression | 0.563 | (0.359–0.885) | 0.013 |
| M | Model L+TIL | 0.623 | (0.395–0.982) | 0.042 |
| N | Model M+neurotropism | 0.270 | ||
| O | Model M+vertical growth phase | 0.357 |
Age, <50 vs. ≥50 years; site of lesion, trunk vs. extremities; histology 1, superficial spreading vs. others; Clark's level, I–III vs. IV–V; Breslow's thickness, <2 vs. ≥2 mm; neurotropism, present vs. absent; mitotic rate, ≤3 vs. >3/mm2; ulceration, present vs. absent; vertical growth phase, present vs. absent; TIL, present vs. absent; regression, present vs. absent; precursor lesion, present vs. absent; BRAF, positive vs. negative; node 1, presence of lymph node involvement (yes vs. no); metastasis 1, presence vs. absence; recurrence, yes vs. no; sex, male vs. female. HR, hazard ratio; CI, confidence interval; TIL, tumor-infiltrating lymphocytes.